The expression of TET1 is greater in tumors that harbor isocitrate dehydrogenase (IDH) mutations (Supplemental Fig. 1C) in both GBM and low-grade gliomas (Supplemental Fig. 1D). This evidence concerns the gene IDH3A and central nervous system cancer.